CompanyRGENNasdaqWaltham, MA

Repligen Corp

Repligen develops bioprocessing technologies and systems for biopharmaceutical manufacturing, including filtration, chromatography, process analytics, and protein purification platforms.

Stories only

SEC EDGAR ClinicalTrials.gov repligen.com

8-KSep 15Latest SEC filing, period to Sep 10

Sep 15Latest story

September 2026

Repligen board member Karen Dawes to retire after over 20 years

Sep 15PeopleRepligen Corp

July 2026

Repligen raises 2026 guidance after 13% organic revenue growth in Q2

Jul 28Quarterly updateRepligen Corp

Repligen-BioLife merger agreement includes $59 million termination fee, January 2027 outside date

Jul 22M&ARepligen Corp